Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR

Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR is a phase 2, interventional study registered as NCT07651007 by Wang Xin, with a registry enrolment figure of 29 participants, started 2026-05-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: iTNT-HX02. Conditions listed: Advanced Rectal Cancer. Primary outcome: Complete response rate. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal adenocarcinoma with immunohistochemistry and/or genetic testing showing MSS/pMMR status;". No results are recorded here; the registry entry is the source.